声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。5月7日，百济神州发布2025Q1财报，2025年第一季度总收入为80.48亿元，同比增长50.2%，总收入的增长主要得益于百悦泽®（泽布替尼）在美国和欧洲的销售额增长。其产品收入为79.85亿元，同比增长49.9%。产品收入的增长主要得益于泽布替尼的...
Source Link声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。5月7日，百济神州发布2025Q1财报，2025年第一季度总收入为80.48亿元，同比增长50.2%，总收入的增长主要得益于百悦泽®（泽布替尼）在美国和欧洲的销售额增长。其产品收入为79.85亿元，同比增长49.9%。产品收入的增长主要得益于泽布替尼的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.